The Global Story: Will the new cancer vaccine survive RFK Jr’s America?

mRNA technology represents a transformative frontier in medicine, shifting from a long-dismissed scientific pursuit to a breakthrough platform for personalized cancer vaccines. By training the immune system to recognize and attack specific tumor cells, this technology offers a more targeted approach than traditional treatments. While the COVID-19 pandemic proved the efficacy and speed of mRNA platforms, it simultaneously fueled intense political polarization. U.S. Health and Human Services Secretary RFK Jr. has recently curtailed federal funding for mRNA research, citing concerns over safety and efficacy for respiratory viruses. Science writer Tom Whipple notes that these policy shifts contradict clinical data and threaten to drive critical research and talent out of the United States. Despite this political friction, the private sector continues to advance mRNA applications, particularly for treating complex cancers where the potential benefits far outweigh the risks.